Dr. Lal Pathlabs Limited

BSE: 539524 NSE: LALPATHLAB
Dr. Lal Pathlabs Limited - healthcare in New Delhi, Delhi, India. FY 2026 financials & compliance.
CIN L74899DL1995PLC065388 Incorporated 14 February 1995 ROC Delhi HQ New Delhi, Delhi, India
Active Listed - NSE: LALPATHLAB · BSE: 539524 Public Limited Company healthcare
Data last updated
Market Cap
₹32,920 Cr
LALPATHLAB · NSE
Share Price
₹1,952.30
-0.46% today
Revenue
₹2,763 Cr
FY 2025-26 · +13.9% YoY
EBITDA
₹752 Cr
Margin 27.2%
Net Profit
₹522 Cr
FY 2025-26 · +8.1% YoY
P/E (TTM)
57.4x
P/B 12.9x
ROE
21.8%
ROCE 27.4%
Debt / Equity
0.08
Interest cover 3.9x

About Dr. Lal Pathlabs Limited

Data last updated: 25 September 2026

Dr. Lal Pathlabs Limited is a public limited company based in New Delhi, Delhi, India. It specialises in diagnostic centers and pathology labs, a part of the broader healthcare sector. Incorporated on 14 February 1995, the company has been in operation for over 31 years.

Registered with ROC Delhi under CIN L74899DL1995PLC065388. Listed on BSE: 539524 and NSE: LALPATHLAB.

Capital: an authorised share capital of ₹200 Cr and a paid-up capital of ₹167.64 Cr. Formerly known as Dr. Lal Pathlabs Private Limited. It is led by directors including Archana Lal Erdmann and Arvind Lal.

Last AGM: 28 June 2025. Financial statements filed for year ended 31 March 2025. Office: Block E Sector – 18 Rohini, New Delhi, Delhi, India – 110085.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,762.91 Cr, a growth of 12.25% compared to the previous year. The net worth stands at ₹2,508.14 Cr (up 15.44% YoY). Total assets are valued at ₹2,742.93 Cr (up 15.94% YoY).

The company has a workforce of approximately 4,081 employees as per the latest available data. Its group structure includes 8 subsidiaries.

The company is associated with 1 brand - Dr Lal Pathlabs. As per MCA filings, the company has open charges of ₹225.06 Cr and satisfied charges of ₹343.8 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lalpathlabs.com.

Company Details of Dr. Lal Pathlabs Limited
CIN L74899DL1995PLC065388
Registration Number 065388
Incorporation Date 14 February 1995
ROC Delhi
Listing Status Listed (BSE: 539524, NSE: LALPATHLAB)
Company Status Active
Date of Last AGM 28 June 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Arvind Lal Whole-Time Director Vandana Lal Whole-Time Director Archana Lal Erdmann Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    lalpathlabs.com
  • Social Media
  • Apps
  • Registered Address
    Block E Sector – 18 Rohini, New Delhi, Delhi, India – 110085
  • Industry
    Healthcare, Diagnostic Centers & Pathology Labs
Company report
Dr. Lal Pathlabs Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Dr. Lal Pathlabs Limited report

Financials, compliance, directors, charges, ownership and filings for Dr. Lal Pathlabs Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Dr. Lal Pathlabs Limited

Dr. Lal Pathlabs Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74899DL1995PLC065388, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L74899DL1995PLC065388 Current
U74899DL1995PTC065388 Previous
U74899DL1995PLC065388 Previous

Associated Brands with Dr. Lal Pathlabs Limited

Dr. Lal Pathlabs Limited operates one associated brand: Dr Lal PathLabs. These brands represent Dr. Lal Pathlabs Limited's diversified market presence and brand portfolio.

Brand Description Website
Dr Lal PathLabs
Chain of pathology and radiology labs lalpathlabs.com

Competitors & Alternatives of Dr. Lal Pathlabs Limited

Brands and companies operating in the same space as Dr. Lal Pathlabs Limited include Redcliffe Labs, Metropolis India, Orange health and 4 more.

Competitor Description Location Founded
Redcliffe Labs Redcliffe Labs Home-based diagnostic tests are booked via an online platform. Noida, India, India 2018
Metropolis India Metropolis India Diagnostic centers are operated as a nationwide chain. Mumbai, India, India 1981
Orange health Orange health At-home diagnostic tests are booked and collected by phlebotomists. Bengaluru, India, India 2020
Agilus Diagnostics Agilus Diagnostics Leading diagnostic chain providing quality blood test and full body checkup services Gurugram, India, India 1995
Apollo Diagnostics Apollo Diagnostics Provides pathology lab tests, health check packages, and home sample collection. Hyderabad, India, India 2015
Sterling Accuris Diagnostics Sterling Accuris Diagnostics Pathology diagnostic services are offered via a chain of labs. Ahmedabad, India, India 2015
Airmed Airmed Provider of a chain of diagnostic labs Ahmedabad, India, India 2016

Business Activity of Dr. Lal Pathlabs Limited

Dr. Lal Pathlabs Limited is engaged in the principal business activity of hospital and medical care, with detailed activities including medical and dental practice, nursing, pathology, blood bank services, etc..

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
Q Hospital and Medical Care Q2 Medical and dental practice, Nursing, pathology, blood bank services, etc. Locked
Premium access

Business activity turnover details for Dr. Lal Pathlabs Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Dr. Lal Pathlabs Limited

Dr. Lal Pathlabs Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
Deloitte Haskins & Sells LLP Locked Locked Locked
Premium access

Complete auditor history for Dr. Lal Pathlabs Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Dr. Lal Pathlabs Limited

Dr. Lal Pathlabs Limited is currently managed by 9 directors, with 16 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Archana Lal Erdmann
Also directs: Dr. Lal Pathlabs Limited, Genecode Health Private Limited
Director 17 May 2019 7 Years 4 Months Current
Arvind Lal
Also directs: Dr. Lal Pathlabs Limited, Archana Pharmaceuticals Private Limited, Kalmatia Sangam Travels Private Limited and 4 more
Whole-Time Director 14 Feb 1995 31 Years 7 Months Current
Arun Duggal
Also directs: J B Chemicals And Pharmaceuticals Limited, Dr. Lal Pathlabs Limited, Davenport Management Consultants Services Private Limited
Director 02 Feb 2023 3 Years 7 Months Current
Vandana Lal
Also directs: Dr. Lal Pathlabs Limited, Archana Pharmaceuticals Private Limited, Kalmatia Sangam Travels Private Limited
Whole-Time Director 14 Feb 1995 31 Years 7 Months Current
Rahul Sharma
Also directs: Dr. Lal Pathlabs Limited, Porst Ware Llp, Chimes Aviation Private Limited
Director 22 Jul 2005 21 Years 2 Months Current
Somya Satsangi
Also directs: Dr. Lal Pathlabs Limited, Tlgs Consulting Group Private Limited
Director 08 Feb 2019 7 Years 7 Months Current
Showing 6 of 9 current directors. View all directors

Financials of Dr. Lal Pathlabs Limited FY 2025-26 filings available

Dr. Lal Pathlabs Limited reported revenue of ₹2,762.91 Cr (up 12.25% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,763 Cr
+12.2% YoY
EBITDA
₹752 Cr
+8.2% YoY
Profit After Tax
₹522 Cr
+8.1% YoY
Net Worth
₹2,508 Cr
+15.4% YoY
Total Assets
₹2,743 Cr
+15.9% YoY
Total Debt
₹199 Cr
+26.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,7632,4612,2272,0172,0871,5811,330
Revenue growth+13.9%+9.2%+5.9%+0.0%+33.3%+16.0%+8.5%
EBITDA752696609490561436344
EBITDA margin+27.2%+28.3%+27.4%+24.3%+26.9%+27.6%+25.8%
Profit before tax669625505344475394311
Net profit522483358238345292226
Net profit margin+18.9%+19.6%+16.1%+11.8%+16.5%+18.5%+17.0%
EPS (₹)30.1358.2842.8528.6541.3734.9927.11
Balance sheet
Total assets2,7432,3662,1342,1192,0701,4261,147
Net worth2,5082,1731,8491,6661,5021,2451,033
Total debt1991572474205321500.00
Cash & bank910839830665618926569
Net working capital747689693560537852501
Cash flow
Cash from operations636569535456447398284
Cash from investing(422)(303)(24.27)(287)(449)(212)(26.11)
Cash from financing(264)(334)(414)(283)136(139)(190)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue798703660731670603597660
Revenue growth (YoY)+19.1%+16.6%+10.6%+10.7%+11.3%+10.5%+10.7%+9.8%
Other income31.9024.0024.4024.8028.1025.8025.1021.90
EBITDA248187149224192169154202
EBITDA margin+31.0%+26.6%+22.6%+30.7%+28.7%+28.0%+25.8%+30.7%
Depreciation44.4044.6042.1040.5034.6036.4035.5035.30
Interest6.306.107.204.804.705.005.306.00
Profit before tax229160124204181153138183
Tax58.2027.9032.9051.4047.10(2.10)40.2052.30
Net profit17013291.4015213415698.10131
EPS (₹)10.137.855.4118.0515.8518.5411.5815.48
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,6482,3522,1251,7691,8791,4911,274
Revenue growth+14.1%+9.2%+18.1%-4.2%+26.1%+14.5%+7.2%
EBITDA724665581461512407328
EBITDA margin+27.3%+28.3%+27.3%+26.0%+27.3%+27.3%+25.7%
Profit before tax660621483391461374303
Net profit527490347291345280223
Net profit margin+19.9%+20.8%+16.3%+16.5%+18.4%+18.8%+17.5%
EPS (₹)30.3359.4941.5435.0741.4233.6126.78
Balance sheet
Total assets2,6662,2852,0412,0851,9781,3211,107
Net worth2,4732,1341,8011,6901,4721,2171,016
Total debt1931511422813850.000.00
Cash & bank844768752534543889549
Net working capital712640628434466787492
Cash flow
Cash from operations606540478428426373272
Cash from investing(382)(293)31.91(288)(449)(195)(19.47)
Cash from financing(256)(325)(404)(270)141(136)(187)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue764675632700641577569631
Revenue growth (YoY)+19.3%+17.0%+11.1%+10.9%+11.5%+10.8%+19.6%+18.7%
Other income29.9037.0026.6022.8026.3025.2031.3024.20
Total expenses526494488484457418418437
EBITDA238182144215183159151194
EBITDA margin+31.2%+26.9%+22.7%+30.7%+28.6%+27.6%+26.5%+30.7%
Depreciation40.0042.7040.1038.5032.8034.6033.6033.40
Interest6.105.907.004.604.504.805.105.80
Profit before tax222170123195172145144179
Tax56.4028.8031.0049.1043.10(3.50)38.2050.20

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue798703660731670603597660
Revenue growth (YoY)+19.1%+16.6%+10.6%+10.7%+11.3%+10.5%+10.7%+9.8%
Other income31.9024.0024.4024.8028.1025.8025.1021.90
EBITDA248187149224192169154202
EBITDA margin+31.0%+26.6%+22.6%+30.7%+28.7%+28.0%+25.8%+30.7%
Depreciation44.4044.6042.1040.5034.6036.4035.5035.30
Interest6.306.107.204.804.705.005.306.00
Profit before tax229160124204181153138183
Tax58.2027.9032.9051.4047.10(2.10)40.2052.30
Net profit17013291.4015213415698.10131
EPS (₹)10.137.855.4118.0515.8518.5411.5815.48
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,7632,4612,2272,0172,0871,5811,330
Revenue growth+13.9%+9.2%+5.9%+0.0%+33.3%+16.0%+8.5%
Other income10193.4369.1741.7252.5551.3355.05
Total expenses2,0101,7661,6171,5271,5271,145987
Employee cost503456425377365274243
EBITDA752696609490561436344
EBITDA margin+27.2%+28.3%+27.4%+24.3%+26.9%+27.6%+25.8%
Depreciation16214214415010877.2072.81
Interest22.8022.3129.3637.5330.1816.0015.31
Profit before tax669625505344475394311
Tax15913314310312597.9382.91
Net profit522483358238345292226
Net profit margin+18.9%+19.6%+16.1%+11.8%+16.5%+18.5%+17.0%
EPS (₹)30.1358.2842.8528.6541.3734.9927.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16883.5983.4883.3783.4883.4683.35
Reserves & surplus2,3412,0891,7661,5831,4181,162974
Shareholders' funds (net worth)2,5082,1731,8491,6661,5021,2451,033
Minority interest33.1433.7636.0833.2535.4630.9621.22
Secured loans0.000.000.001532620.000.00
Unsecured loans1991572472662701500.00
Total debt1991572474205321500.00
Total liabilities2,7432,3662,1342,1192,0701,4261,147
Assets
Gross block2,1801,9381,8621,8071,726684574
Net block1,2561,1681,2281,3051,369447413
Capital work in progress6.543.485.654.9415.009.6111.38
Investments42332711415065.4659.30164
Inventories43.8636.1337.3133.8152.5442.5656.96
Sundry debtors11188.1277.4070.8285.4066.7051.39
Cash & bank balances910839830665618926569
Loans & advances79.8273.8967.9053.1054.1650.5850.91
Total current assets1,1441,0371,0138238101,086728
Total current liabilities397348320264273234227
Net working capital747689693560537852501
Total assets2,7432,3662,1342,1192,0701,4261,147
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash293361264378244197129
Net cash from operating activities636569535456447398284
Net cash from investing activities(422)(303)(24.27)(287)(449)(212)(26.11)
Net cash from financing activities(264)(334)(414)(283)136(139)(190)
Net change in cash(49.83)(68.31)97.20(114)13447.5867.33
Closing cash910839830665618926569
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.3%+10.5%+10.4%-3.4%+32.0%+18.9%+10.6%
EBITDA growth+8.2%+14.2%+24.4%-12.6%+28.5%+27.0%+17.0%
PBT growth+7.1%+23.6%+47.0%-27.6%+20.4%+27.0%+3.3%
Net income growth+8.1%+34.9%+50.2%-31.0%+18.3%+29.2%+13.4%
Revenue CAGR (3Y)+11.1%+5.7%+12.1%+14.9%+20.2%+14.4%+13.4%
EBITDA CAGR (3Y)+15.4%+7.5%+11.8%+12.6%+24.1%+18.2%+13.1%
Profitability & leverage
Net income margin+18.5%+20.0%+16.3%+12.0%+16.8%+18.8%+17.1%
Return on capital employed+27.5%+29.2%+25.6%+18.5%+29.5%+32.6%+31.4%
Return on net worth+21.8%+24.5%+20.6%+15.2%+25.5%+26.0%+23.0%
Debt / equity0.080.100.190.300.250.070.00
Long-term debt / equity0.050.050.090.160.150.050.00
Interest cover3.864.036.3111.056.674.465.65
Efficiency & per share
Fixed asset turnover1.341.301.211.141.732.513.04
Inventory turnover69.0867.0362.6246.7143.9031.7831.12
Debtors turnover27.7929.7430.0525.8227.4526.7825.43
EPS (₹)30.1358.2842.8528.6541.3734.9927.11
Dividend per share (₹)20.5024.0024.0012.0012.0020.0012.00
Book value per share (₹)149.69259.92221.53199.87180.17149.39126.81
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue764675632700641577569631
Revenue growth (YoY)+19.3%+17.0%+11.1%+10.9%+11.5%+10.8%+19.6%+18.7%
Other income29.9037.0026.6022.8026.3025.2031.3024.20
Total expenses526494488484457418418437
EBITDA238182144215183159151194
EBITDA margin+31.2%+26.9%+22.7%+30.7%+28.6%+27.6%+26.5%+30.7%
Depreciation40.0042.7040.1038.5032.8034.6033.6033.40
Interest6.105.907.004.604.504.805.105.80
Profit before tax222170123195172145144179
Tax56.4028.8031.0049.1043.10(3.50)38.2050.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,6482,3522,1251,7691,8791,4911,274
Revenue growth+14.1%+9.2%+18.1%-4.2%+26.1%+14.5%+7.2%
Other income11311266.3046.6053.1051.2757.61
Total expenses1,9241,6861,5441,3081,3661,083946
Employee cost475431403316321257232
EBITDA724665581461512407328
EBITDA margin+27.3%+28.3%+27.3%+26.0%+27.3%+27.3%+25.7%
Depreciation15413413682.0975.9469.7868.01
Interest22.0421.5028.6034.3828.6314.8314.66
Profit before tax660621483391461374303
Tax15212413698.4711693.9479.58
Net profit527490347291345280223
Net profit margin+19.9%+20.8%+16.3%+16.5%+18.4%+18.8%+17.5%
EPS (₹)30.3359.4941.5435.0741.4233.6126.78
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16883.5983.4883.3783.3583.3583.35
Reserves & surplus2,3052,0511,7171,6061,3891,154957
Shareholders' funds (net worth)2,4732,1341,8011,6901,4721,2171,016
Secured loans0.000.0083.332373450.000.00
Unsecured loans19315158.8843.9639.350.000.00
Total debt1931511422813850.000.00
Total liabilities2,6662,2852,0412,0851,9781,3211,107
Assets
Gross block2,0131,7741,701736667520449
Net block1,1431,0511,104361371300297
Capital work in progress6.543.485.654.9414.458.9911.29
Investments5134162131,2131,062171253
Inventories40.6032.2732.8523.3439.8438.9455.00
Sundry debtors13410587.4763.3267.0263.5450.25
Cash & bank balances844768752534543889549
Loans & advances76.6870.3864.1247.9149.5547.9849.08
Total current assets1,0959769366696991,039704
Total current liabilities383336308235233252211
Net working capital712640628434466787492
Total assets2,6662,2852,0412,0851,9781,3211,107
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash267344220351233189124
Net cash from operating activities606540478428426373272
Net cash from investing activities(382)(293)31.91(288)(449)(195)(19.47)
Net cash from financing activities(256)(325)(404)(270)141(136)(187)
Net change in cash(32.17)(77.75)106(131)11842.4265.30
Closing cash844768752534543889549
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.6%+10.7%+20.1%-5.8%+26.1%+17.0%+9.3%
EBITDA growth+8.8%+14.6%+26.0%-10.1%+25.8%+24.3%+15.9%
PBT growth+6.3%+28.8%+23.5%-15.2%+23.3%+23.6%+3.6%
Net income growth+7.5%+41.2%+19.1%-15.6%+23.1%+25.6%+14.2%
Revenue CAGR (3Y)+14.4%+7.8%+12.6%+11.6%+17.3%+13.3%+13.0%
EBITDA CAGR (3Y)+16.3%+9.1%+12.5%+12.0%+21.9%+16.7%+12.5%
Profitability & leverage
Net income margin+19.2%+21.2%+16.3%+16.5%+18.4%+18.8%+17.5%
Return on capital employed+27.6%+29.7%+24.8%+20.9%+29.7%+32.0%+31.1%
Return on net worth+22.1%+25.3%+19.9%+18.5%+25.7%+25.1%+22.9%
Debt / equity0.070.070.120.210.140.000.00
Long-term debt / equity0.050.020.020.080.060.000.00
Interest cover3.874.056.439.086.564.395.64
Efficiency & per share
Fixed asset turnover1.401.351.742.523.163.083.58
Inventory turnover72.6772.2275.6456.0047.7031.7330.76
Debtors turnover22.1024.3928.1927.1428.7826.2024.65
EPS (₹)30.3359.4941.5435.0741.4233.6126.78
Dividend per share (₹)20.5024.0018.0012.0012.0020.0012.00
Book value per share (₹)147.58255.32215.71202.70176.63148.43124.83
Want more history and ratios?
You're viewing the latest exchange-filed financials for Dr. Lal Pathlabs Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Dr. Lal Pathlabs Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 53.20%, foreign institutional investors hold 17.40%, domestic institutional investors hold 21.60%, retail and other public shareholders hold 7.80% of Dr. Lal Pathlabs Limited.

Promoters: 53.20%DII (Domestic Institutional): 21.60%FII (Foreign Institutional): 17.40%Retail & Others: 7.80%
Jun 2026
QUARTER
53.20% Promoters
21.60% DII (Domestic Institutional)
17.40% FII (Foreign Institutional)
7.80% Retail & Others
Promoter holding - history
Now 53.20% · Jun 2026High 53.20% · Sep 2025Low 53.20% · Sep 2025
52%52.8%53.5%54.3%55%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 53.20%Dec 2025: 53.20%Mar 2026: 53.20%Jun 2026: 53.20%53.20%53.20%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters53.20%53.20%53.20%53.20%
Public46.80%46.80%46.80%46.80%

Group Structure of Dr. Lal Pathlabs Limited

Dr. Lal Pathlabs Limited has 8 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Dr. Lal Pathlabs Limited's business expansion strategy and organizational complexity.

8
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Paliwal Diagnostics Private Limited U26914UP1997PTC022257 -
Centrapath Labs Private Limited U74220MP2019PTC049171 -
Dr. Lal Ventures Private Limited U85100DL2018PTC342828 -
Suburban Diagnostics (India) Private Limited U85110MH2002PTC136144 -
Paliwal Medicare Private Limited U85110UP2006PTC031606 -
Aprl Pathlabs Private Limited U85195GJ2019PTC110176 -

Showing major subsidiaries. Total: 8.

Charges & Borrowings of Dr. Lal Pathlabs Limited

Open charges
₹225.06 Cr
Satisfied charges
₹343.8 Cr
Breakdown by lending institutions
Axis Bank Limited₹185.00 Cr
Others₹40.00 Cr
State Bank of Baroda₹0.06 Cr
Latest charge details
DateLenderAmountStatus
10 Nov 2021 Others ₹40 Cr Open
09 Nov 2021 Axis Bank Limited ₹185 Cr Open
19 Apr 1988 State Bank of Baroda ₹6.13 Lakh Open
24 Jun 2022 Hdfc Bank Limited ₹250 Cr Satisfied
07 Dec 2020 Others ₹10 Cr Satisfied

Total charge records: 17 View all charges

Employees and EPFO Compliance at Dr. Lal Pathlabs Limited

Dr. Lal Pathlabs Limited has a workforce of 4,081 employees as of Apr 01, 2024.

Employee count
4,081
Active EPFO establishments
3
Employee growth
-0.1%
Premium access

Employee and EPFO history for Dr. Lal Pathlabs Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Dr. Lal Pathlabs Limited

Premium access

GST registrations and filing compliance for Dr. Lal Pathlabs Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Dr. Lal Pathlabs Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Dr. Lal Pathlabs Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Dr. Lal Pathlabs Limited

Premium access

MSME payment history for Dr. Lal Pathlabs Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Dr. Lal Pathlabs Limited

Premium access

Corporate group structure for Dr. Lal Pathlabs Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Dr. Lal Pathlabs Limited

Premium access

MCA filings and documents for Dr. Lal Pathlabs Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Dr. Lal Pathlabs Limited

Activity
28 Jun 2025
Dr. Lal Pathlabs Limited last Annual general meeting of members was held on 28 Jun 2025 as per latest MCA records.
Activity
31 Mar 2025
Dr. Lal Pathlabs Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi Ii.
Charges
10 Mar 2025
A charge registered on 24 Jun 2022 via Charge ID 100594143 with Hdfc Bank Limited was fully satisfied on 10 Mar 2025.
Directors
04 Sep 2024
Ved Prakash Goel was appointed as a Cfo on 04 Sep 2024 & has been associated with this company since 2 years 22 days.
Directors
30 May 2024
Shankha Banerjee was appointed as a Ceo on 30 May 2024 & has been associated with this company since 2 years 3 months.
Directors
27 Jul 2023
Rajit Mehta was appointed as a Director on 27 Jul 2023 & has been associated with this company since 3 years 2 months.

Recent News on Dr. Lal Pathlabs Limited

Stocks that will see action today January 30, 2025
30 Jan 2025 · Thehindubusinessline

Frequently Asked Questions about Dr. Lal Pathlabs Limited

Dr. Lal Pathlabs Limited is an active public limited company in the healthcare sector based in New Delhi, Delhi, India. It was incorporated on 14 February 1995 (31+ years old) and is registered under CIN L74899DL1995PLC065388. Listed on BSE: 539524 and NSE: LALPATHLAB. The company has 4,081 employees.

Dr. Lal Pathlabs Limited reported revenue of ₹2,762.91 Cr for FY 2025-26 (up 12.25% YoY) based on consolidated financials.

The current directors of Dr. Lal Pathlabs Limited are:

The primary industry of Dr. Lal Pathlabs Limited is healthcare. The company specifically operates in diagnostic centers and pathology labs. The company is currently active in this sector.

Yes. Dr. Lal Pathlabs Limited is listed on both BSE (code: 539524) and NSE (symbol: LALPATHLAB).

Dr. Lal Pathlabs Limited can be reached at the registered office: Block E Sector – 18 Rohini, New Delhi, Delhi, India – 110085, or through the website lalpathlabs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available